Il­lu­mi­na co-founder Mark Chee moves from the genome to the pro­teome with up­start En­co­dia

When Mark Chee co-found­ed Il­lu­mi­na in 1998, the ge­nomics field was just heat­ing up. It had been three years since the first bac­teri­um genome was se­quenced, but the Hu­man Genome Project was still years away from com­ple­tion. That space has since erupt­ed, and now Chee is on to what re­searchers think is the next big thing: pro­teomics.

Chee and fel­low Il­lu­mi­na vet­er­an Kevin Gun­der­son co-found­ed pro­tein se­quenc­ing-fo­cused En­co­dia back in 2015. Af­ter keep­ing qui­et for the last few years, the up­start broke the si­lence on Wednes­day to spread the word of its $75 mil­lion Se­ries C round, led by North­pond Ven­tures and Deer­field Man­age­ment. The funds will be used to com­mer­cial­ize En­co­dia’s patent­ed pro­tein analy­sis plat­form, dubbed Pro­teoCode.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.